Net Income (Loss) Per Share

6 Months Ended

Jun. 30, 2025

9. Net income (loss) per share

The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands except share and per share amounts):


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025		2024
Numerator:
Net income (loss)	$	(23,483	)	$	(25,695	)	$	89,397	$	(52,069	)
Denominator:
Weighted-average number of common shares, basic		58,353,855			55,765,948			58,109,622		51,288,222
Weighted-average number of common shares, diluted		58,353,855			55,765,948			59,681,472		51,288,222
Net income (loss) per share, basic	$	(0.40	)	$	(0.46	)	$	1.54	$	(1.02	)
Net income (loss) per share, diluted	$	(0.40	)	$	(0.46	)	$	1.50	$	(1.02	)

As the Company had net income during the six months ended June 30, 2025, the Company’s potential dilutive securities, which include stock options, restricted stock units and performance stock units, were included in the calculation of diluted net income per share attributable to common stockholders. For the three months ended June 30, 2025 and for the three and six months ended June 30,

2024, the Company’s potential dilutive securities, which include stock options, restricted stock units and performance stock units have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same for the three months ended June 30, 2025 and for the three and six months ended June 30, 2024.

The Company excluded the following potential common stock, presented based on amounts outstanding at June 30, 2025 and 2024 from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect.


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Outstanding options to purchase common stock		9,523,757		8,064,604		7,408,212		8,064,604
Restricted stock units		1,797,643		2,018,957		544,976		2,018,957
Performance stock units		219,000		372,000		—		372,000
Total		11,540,400		10,455,561		7,953,188		10,455,561

Stoke Therapeutics, Inc. 10-Q